# This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma.

> **NCT00032903** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sigma-Tau Research, Inc.** · enrollment: 59 (estimated)

## Conditions studied

- Malignant Glioma

## Interventions

- **DRUG:** Gimatecan® (ST 1481)

## Key facts

- **NCT ID:** NCT00032903
- **Lead sponsor:** Sigma-Tau Research, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** —
- **Final completion:** 2005-10
- **Target enrollment:** 59 (ESTIMATED)
- **Last updated:** 2009-06-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00032903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00032903, "This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00032903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*